A SYSTEM APPROACH TO PHARMACODYNAMICS .3. AN ALGORITHM AND COMPUTER-PROGRAM, COLAPS, FOR PHARMACODYNAMIC MODELING

被引:26
作者
VENGPEDERSEN, P [1 ]
MANDEMA, JW [1 ]
DANHOF, M [1 ]
机构
[1] LEIDEN STATE UNIV,SYLVIUS LAB,CTR BIOPHARMACEUT SCI,2312 AV LEIDEN,NETHERLANDS
关键词
D O I
10.1002/jps.2600800518
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Many pharmacodynamic (PD) models may be generalized in the form E(t) = N(L[c(t)]), where E(t) is a recorded effect response, c(t) is a sampled drug level, N is a nonlinear autonomic function, and L is a linear operator that commonly is a convolution operation. The NL class of PD models includes the traditional effect compartment PD models as a subclass, but is not limited to such models. An algorithm and computer program named COLAPS, based on system analysis principles and hysteresis minimization, that enable N and L to be empirically determined for the NL class of models without addressing specific kinetic structure aspects ("model independence") are presented. The kinetic concepts of biophase conduction and transduction functions are used by COLAPS. Such an approach is more general than the effect compartment approaches because it does not assume first-order transport principles. The pitfalls of hysteresis minimization in PD modelling are discussed and the procedures taken by COLAPS to avoid these pitfalls are outlined. A transformation technique prevents improper convergence to a point. A novel reparameterization scheme is introduced that maximizes the flexibility of the kinetic functions and extends the generality of the analysis. Inequality function constraints are maintained without the need for troublesome constrained nonlinear optimization procedures. Usage of the COLAPS program is illustrated in the analysis of the PD of amobarbital. The COLAPS program resulted in an excellent minimization of the effect versus biophase level hysteresis. The biophase conduction function, the biophase drug level (normalized), and the transduction curve were determined. The transduction curve showed clear biphasic behavior.
引用
收藏
页码:488 / 495
页数:8
相关论文
共 18 条
[1]   PHARMACOKINETIC PHARMACODYNAMIC MODELING OF CNS DRUG EFFECTS - AN OVERVIEW [J].
DINGEMANSE, J ;
DANHOF, M ;
BREIMER, DD .
PHARMACOLOGY & THERAPEUTICS, 1988, 38 (01) :1-52
[2]   A SYSTEM APPROACH TO PHARMACODYNAMICS .2. GLYBURIDE PHARMACODYNAMICS AND ESTIMATION OF OPTIMAL DRUG DELIVERY [J].
GILLESPIE, WR ;
VENGPEDERSEN, P ;
ANTAL, EJ ;
PHILLIPS, JP .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1988, 77 (01) :48-55
[3]  
Gregory T K, 1986, J Clin Monit, V2, P190, DOI 10.1007/BF01620551
[4]  
HOLFORD NHG, 1981, CRC CR REV BIOM ENG, V5, P273
[5]   UNDERSTANDING THE DOSE-EFFECT RELATIONSHIP - CLINICAL-APPLICATION OF PHARMACOKINETIC-PHARMACODYNAMIC MODELS [J].
HOLFORD, NHG ;
SHEINER, LB .
CLINICAL PHARMACOKINETICS, 1981, 6 (06) :429-453
[6]  
SEGRE G, 1968, FARMACO-ED SCI, V23, P907
[7]   DRUG INPUT OPTIMIZATION - BIOAVAILABILITY-EFFECTED TIME-OPTIMAL CONTROL OF MULTIPLE, SIMULTANEOUS, PHARMACOLOGICAL EFFECTS AND THEIR INTERRELATIONSHIPS [J].
SMOLEN, VF ;
WEIGAND, WA ;
TURRIE, BD .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1972, 61 (12) :1941-&
[8]   RELATIONSHIP BETWEEN DOSE, EFFECT, TIME, AND BIOPHASIC DRUG LEVELS [J].
SMOLEN, VF ;
THEOPHANOUS, TG ;
BARILE, RG .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1972, 61 (03) :467-+
[9]  
THRON CD, 1974, PHARMACOL RES COMMUN, V26, P3
[10]   SIMULTANEOUS MODELING OF PHARMACOKINETICS AND PHARMACODYNAMICS WITH NONPARAMETRIC KINETIC AND DYNAMIC-MODELS [J].
UNADKAT, JD ;
BARTHA, F ;
SHEINER, LB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (01) :86-93